Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: 

• A formal presentation at the Stifel 2023 Healthcare Conference in New York at 4:10 p.m. ET on Tuesday, November 14, 2023. A live webcast will be available using this weblink: https://wsw.com/webcast/stifel83/celc/2056478; and
• A fireside chat at the Jefferies London Healthcare Conference at 8:00 a.m. GMT / 4:00 a.m. ET on Thursday, November 16, 2023. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff287/celc/1825156.

About Celcuity 

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is expected to be initiated in the first quarter of 2024. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at Celcuity.com. Follow us on LinkedIn and Twitter.

View source version of release on GlobeNewswire.com

Contacts:

Celcuity Inc.Brian Sullivan, [email protected]Vicky Hahne, [email protected](763) 392-0123

ICR WestwickeMaria Yonkoski, [email protected] (203) 682-7167

You May Also Be Interested In

• Membrane Solutions Launches New Outdoor Water Filtration Solutions at Outdoor Retailer 2026
• Idealist Celebrates Thirty Years of Helping People Move From Intention to Action
• Green Electricity Illuminates Indoor Ski Resort in Central China